Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Savient Receives FDA’s Complete Response Letter For KRYSTEXXA
Savient has received a complete response letter from FDA. The agency stated that it can not approve the company’s Biologics License Application (BLA) for KRYSTEXXA (pegloticase) at this
Savient has received a complete response letter from FDA. The agency stated that it can not approve the company’s Biologics License Application (BLA) for KRYSTEXXA (pegloticase) at this
Purdue and Transcept have entered into an exclusive license and collaboration agreement to commercialize Intermezzo (zolpidem tartrate sublingual) tablet in the US. Transcept has granted Purdue and a
Beckman has completed the acquisition of Olympus’ lab-based diagnostics business. Scott Garrett, chairman, president and chief executive officer of Beckman, said: The completion of this transaction adds considerable
OSI has provided results from the phase III SATURN study on Tarceva (erlotinib). Tarceva extended the survival of patients with advanced non-small cell lung cancer (NSCLC), when used
AstraZeneca and Bristol-Myers Squibb have reported that FDA has approved Onglyza (saxagliptin) for the treatment of type 2 diabetes mellitus in adults. Onglyza is indicated as an adjunct
Germany-based Merck has presented new data from a meta-analysis of trials evaluating the addition of Erbitux (cetuximab) to standard first-line chemotherapy, in patients with non-small cell lung cancer
Total has reported second quarter adjusted net income of E1.7 billion, a decrease of 54 % for the second quarter of 2009, compared to the previous year. The
QuantRx has formed a joint venture with NuRx, to accelerate efforts to capitalize opportunities in the fast growing market for Point-of-Care (POC) products. In addition to benefiting from
Merge Healthcare has signed a new contract with the Center for Diagnostic Imaging (CDI) based in Minneapolis, MN. The solution will debut at the CDI center in Sartell,
FDA’s Arthritis Advisory Committee has confirmed that it will review Auxilium’s Xiaflex during an advisory committee hearing at the Holiday Inn in Gaithersburg, MD, on September 16, 2009.